Navigation Links
Patheon to Host Complimentary Seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”

(PRWEB) June 04, 2013

Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”. The seminar will be held on Tuesday, June 25, 2013 at 11:30 a.m. to 5:30 p.m. Central European Time at the Hilton Hotel in Basel, Switzerland.

In the upcoming seminar, Patheon has invited four scientific leaders to share their experiences and answer questions on successfully progressing to, as well as advancing beyond first-in-man studies. Presentations will be provided by Patheon employees, Jon Sutch, Ph.D., and Roman Hlodan, Ph.D., as well as from Massimo Bresciani from Research Center Pharmaceutical Engineering GmbH, Austria, and Fintan Walton, Ph.D., from PharmaVentures Ltd., UK.

Through case studies and interactive presentations, presenters will discuss formulation strategies to progress to first-in-man for solid, sterile and biopharmaceutical products. In addition, Dr. Walton will present strategies to maximizing the value of an asset from the perspective of an investor.

Visit the company’s website at to learn more or register for the upcoming seminar. Seating is limited.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 17 locations, including 13 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
9. Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
10. Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing”
11. Patheon to Host Webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds”
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):